The Current Landscape of Glioblastoma Biomarkers in Body Fluids.
Cancers (Basel)
; 15(15)2023 Jul 26.
Article
em En
| MEDLINE
| ID: mdl-37568620
ABSTRACT
Glioblastoma (GBM) is a highly aggressive and lethal primary brain cancer that necessitates early detection and accurate diagnosis for effective treatment and improved patient outcomes. Traditional diagnostic methods, such as imaging techniques and tissue biopsies, have limitations in providing real-time information and distinguishing treatment-related changes from tumor progression. Liquid biopsies, used to analyze biomarkers in body fluids, offer a non-invasive and dynamic approach to detecting and monitoring GBM. This article provides an overview of GBM biomarkers in body fluids, including circulating tumor cells (CTCs), cell-free DNA (cfDNA), cell-free RNA (cfRNA), microRNA (miRNA), and extracellular vesicles. It explores the clinical utility of these biomarkers for GBM detection, monitoring, and prognosis. Challenges and limitations in implementing liquid biopsy strategies in clinical practice are also discussed. The article highlights the potential of liquid biopsies as valuable tools for personalized GBM management but underscores the need for standardized protocols and further research to optimize their clinical utility.
Texto completo:
1
Base de dados:
MEDLINE
Tipo de estudo:
Guideline
/
Screening_studies
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article